Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
J Clin Anesth ; 26(7): 511-6, 2014 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-25439413

RESUMO

STUDY OBJECTIVE: To evaluate whether ramosetron increases the corrected QT (QTc) interval. DESIGN: Prospective, randomized, controlled study. SETTING: Operating room. PATIENTS: 135 patients undergoing elective laparoscopic cholecystectomy. INTERVENTION: Patients were allocated to three groups to receive ondansetron 4 mg (Group O4), ramosetron 0.3 mg (Group R), or ondansetron 8 mg (Group O8). The study drugs were administered intravenously approximately 15 minutes before the end of surgery. MEASUREMENT: The QT interval for 10 minutes after administration was recorded. The QTc interval was calculated according to the Fridericia (QTcF) formula. The primary outcome was the QTcF interval among the three groups during the 10 minutes after administration of the study drugs. MAIN RESULTS: The QTcF interval was not significantly prolonged after administration of ondansetron 4 mg and ramosetron. It was significantly increased from one minute after administration until 7 minutes after ondansetron 8 mg (Group O8). The QTcF interval was significantly longer in Group O8 at 1, 2, 3, 4, and 5 minutes. CONCLUSIONS: The prophylactic administration 0.3 mg of ramosetron does not increase the QTc interval. Ondansetron 8 mg increases the QTc interval more so than 4 mg of ondansetron.


Assuntos
Antieméticos/efeitos adversos , Benzimidazóis/efeitos adversos , Síndrome do QT Longo/induzido quimicamente , Ondansetron/efeitos adversos , Náusea e Vômito Pós-Operatórios/prevenção & controle , Adulto , Idoso , Anestesia Geral/métodos , Antieméticos/administração & dosagem , Antieméticos/uso terapêutico , Benzimidazóis/administração & dosagem , Benzimidazóis/uso terapêutico , Colecistectomia Laparoscópica , Relação Dose-Resposta a Droga , Eletrocardiografia/efeitos dos fármacos , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Ondansetron/administração & dosagem , Ondansetron/uso terapêutico , Adulto Jovem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA